Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02655354
Other study ID # 20150987
Secondary ID UH3MH106338
Status Completed
Phase N/A
First received
Last updated
Start date October 2015
Est. completion date November 2019

Study information

Verified date July 2021
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overarching goal of this UH2-UH3 proposal is to work with the NIH Health Care Systems Research Collaboratory to develop and implement a large scale, cluster randomized pragmatic clinical trial demonstration project that directly informs national trauma care system policy targeting injured patients with presentations of Posttraumatic Stress Disorder (PTSD) and related comorbidity. Each year in the United States (US), over 30 million individuals present to trauma centers, emergency departments, and other acute care medical settings for the treatment of physical injuries. Multiple chronic conditions including enduring PTSD, alcohol and drug use problems, depression and associated suicidal ideation, pain and somatic symptom amplification, and chronic medical conditions (e.g., hypertension, coronary artery disease, diabetes, and pulmonary diseases) are endemic among physical trauma survivors with and without traumatic brain injuries (TBI). Evidence-based, collaborative care/care management treatment models for PTSD and related comorbidities exist. These care management models have the potential to be flexibly implemented in order to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries; care management models may also be effective in mitigating the impact of the acute injury event on symptom exacerbations in the large subpopulation of injury survivors who already carry a substantial pre-injury burden of multiple chronic medical conditions.


Description:

Primary Aims and Hypotheses The primary aim of the UH3 period is to conduct a pragmatic randomized effectiveness trial of a collaborative care intervention targeting PTSD and comorbid conditions after acute care injury hospitalization. The investigation aims to determine if injured patients receiving the collaborative care intervention demonstrate significant reductions in PTSD symptoms when compared to control patients receiving care as usual. The study also aims to determine if the intervention patients when compared to control patients will demonstrate significant reductions in depressive symptoms, suicidal ideation, and alcohol use problems, and improvements in physical function. The primary hypothesis is that the intervention group when compared to the control group will demonstrate significant reductions in PTSD symptoms over the course of the year after injury. Secondary hypotheses are that intervention patients when compared to control patients will demonstrate, significant reductions in depressive symptoms, significant reductions in alcohol use problems, and improved post-injury physical function. A Priori Secondary Analyses The study team hypothesizes that a subgroup of patients will have persistent PTSD symptoms that will not remit over the longitudinal course of the investigation, regardless of randomization to intervention or control group conditions. The study team also anticipates that readily identifiable baseline clinical, injury and demographic characteristics will be associated with persistent PTSD symptoms over time (e.g., higher PTSD symptom levels, greater pre-injury trauma exposure, intentional injury including firearm related injury mechanisms and other characteristics such as unemployment, as well as other baseline factors). Derived from previous randomized clinical trials, a cumulative burden index has been developed from these baseline characteristics and will be adapted for the current investigation. The study team proposes a series of secondary analyses that adjust for and stratify by baseline characteristics that put patients at risk for persistent symptoms. It is hypothesized that these secondary analyses will identify a subgroup of intervention patients who are not at risk for persistent symptoms and who will demonstrate clinically and statistically significant treatment responses when compared to patients with similar baseline characteristics in the control condition. The study team also hypothesizes that the treatment effects will be greatest at the 1-6 month post-injury time points that are temporally correlated with the period of active intervention.


Recruitment information / eligibility

Status Completed
Enrollment 635
Est. completion date November 2019
Est. primary completion date November 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient currently admitted to inpatient/emergency department for a traumatic injury Exclusion Criteria: - Non-English speaking - Self-inflicted injury - Actively psychotic - Incarcerated or in custody - Less than 35 on PTSD Checklist - Less than 3 items on PTSD medical record screen - Less than 2 pieces of contact information

Study Design


Intervention

Behavioral:
Motivational Interviewing

Cognitive Behavioral Therapy Elements

Care Management

Drug:
Fluoxetine
Anti-depressant
Fluvoxamine
Anti-depressant
Paroxetine
Anti-depressant
Sertraline
Anti-depressant
Citalopram
Anti-depressant
Venlafaxine
Anti-depressant
Duloxetine
Anti-depressant
Mirtazapine
Anti-depressant
Diphenhydramine
Sleep medication
Trazodone
Sleep medication
Prazosin
Sleep medication

Locations

Country Name City State
United States Georgia Regents Augusta Georgia
United States Cedars Sinai Beverly Hills California
United States Jacobi Medical Center Bronx New York
United States The University of Vermont Burlington Vermont
United States University of Cincinnati Cincinnati Ohio
United States Ohio State University Columbus Ohio
United States Baylor Health Care System Dallas Texas
United States UT Southwestern Medical Center Dallas Texas
United States Inova Trauma Center Falls Church Virginia
United States University of Texas Medical Branch at Galveston Galveston Texas
United States Hartford Hospital Hartford Connecticut
United States Eskenazi Health Indianapolis Indiana
United States University of Iowa Iowa City Iowa
United States University of Kentucky Lexington Kentucky
United States The University of Wisconsin Madison Madison Wisconsin
United States Louisiana State University New Orleans Louisiana
United States University of Rochester Rochester New York
United States U.C. Davis Sacramento California
United States Regions Hospital Saint Paul Minnesota
United States The University of Utah Salt Lake City Utah
United States Santa Clara Valley Medical Center San Jose California
United States Honor Health Scottsdale Arizona
United States U.C.L.A. Harbor Torrance California
United States Wake Forest Winston-Salem North Carolina

Sponsors (4)

Lead Sponsor Collaborator
University of Washington National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD. Baseline, 3-month, 6-month, 12-month
Primary Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome. Baseline, 3-month, 6-month, 12-month
Primary Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome. Baseline, 3-month, 6-month, 12-month
Primary Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome. Baseline, 3-month, 6-month, 12-month
Secondary Number of Participants With Suicidal Ideation Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome. Baseline, 3-month, 6-month, 12-month
Secondary Number of Participants Endorsing a Single Item That Assesses Opioid Use Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use. Baseline, 3-month, 6-month, 12-month
Secondary Cognitive Impairment Scale The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome. Baseline, 3-month, 6-month, 12-month
Secondary Brief Pain Inventory A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain. Baseline, 3-month, 6-month, 12-month
Secondary SF-36 Quality of Life The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health. Baseline, 3-month, 6-month, 12-month
Secondary TSOS Patient Satisfaction: Overall Health Care Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. Baseline, 3-month, 6-month, 12-month
Secondary Number of Participants Endorsing a Single Item That Assesses Stimulant Use Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use. Baseline, 3-month, 6-month, 12-month
Secondary Number of Participants Endorsing a Single Item That Assesses Marijuana Use Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use. Baseline, 3-month, 6-month, 12-month
Secondary TSOS Patient Satisfaction: Mental Health Care Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. Baseline, 3 Month, 6 Month, 12 Month
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A